Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #aacr21--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results of an analysis revealing the potential to use its platform for patient stratification and monitoring. Plasma samples from patients with...

Click to view original post